Posted by Michael Wonder on 16 Apr 2026
Health Canada approves Cysklar (cysteamine ophthalmic solution) 0.44% for treatment of corneal crystals in people with cystinosis
15 April 2026 - Leadiant Biosciences today announced that Health Canada has approved Cysklar (cysteamine ophthalmic solution) 0.44%, a topical eye drop solution indicated for the treatment of corneal cystine crystal accumulation in people with cystinosis.
The approval of Cysklar represents a significant milestone for the cystinosis community living in Canada, offering an easy-to-use option for the treatment of the corneal crystals.
